A citation-based method for searching scientific literature

Renata Rodrigues da Cunha Colombo Bonadio, Rodrigo Nogueira Fogace, Vanessa Costa Miranda, Maria Del Pilar Estevez Diz. Clinics (Sao Paulo) 2018
Times Cited: 29







List of co-cited articles
125 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Sarah L Coleridge, Andrew Bryant, Thomas J Lyons, Richard J Goodall, Sean Kehoe, Jo Morrison. Cochrane Database Syst Rev 2019
30
3

Challenges and Opportunities for Immunotherapies in Gynecologic Cancers.
Jung-min Lee, S Percy Ivy, Elise C Kohn. Oncology (Williston Park) 2016
5
20

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, Shannon N Westin, Karen A Cadoo, Geoffrey I Shapiro, Erica L Mayer, Roisin E O'Cearbhaill, Robert L Coleman, Bose Kochupurakkal,[...]. Lancet Oncol 2019
79
3

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
300
3

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
377
3

Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Camille C Gunderson, Ursula Matulonis, Kathleen N Moore. Gynecol Oncol 2018
16
6

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
Roy Kessous, David Octeau, Kathleen Klein, Patricia N Tonin, Celia M T Greenwood, Manuela Pelmus, Ido Laskov, Liron Kogan, Shannon Salvador, Susie Lau,[...]. Gynecol Oncol 2018
12
8

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
330
3

Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Charlotte Abson, Afroditi Karathanasi, Nikolaos Zakynthinakis-Kyriakou, Jake Edward Ryan, Matin Sheriff, Elie Rassy, Nicholas Pavlidis. Invest New Drugs 2020
37
3


BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
Yuqiao Shen, Farah L Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard Elliott, Bing Wang, Christopher J Lord, Leonard E Post, Alan Ashworth. Clin Cancer Res 2013
280
3


The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Nicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, Eleonora Iuliano, Maria Cucè, Francesco Grillone, Angela Salvino, Vito Barbieri, Antonio Russo, Pierfrancesco Tassone,[...]. Crit Rev Oncol Hematol 2018
21
4

Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Viviane C Ruiz-Schutz, Larissa M Gomes, Rodrigo C Mariano, Daniel V P de Almeida, Juliana M Pimenta, Graziela Z Dal Molin, Fabio R Kater, Rosely Yamamura, Nelson F Correa Neto, Fernando C Maluf,[...]. Crit Rev Oncol Hematol 2019
12
8

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2016
249
3

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Maddison Rose, Joshua T Burgess, Kenneth O'Byrne, Derek J Richard, Emma Bolderson. Front Cell Dev Biol 2020
48
3

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Susan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean-Pierre Delord, Antoine Italiano, Jerome Alexandre, Benoit You, Sara Bastian, Matthew G Krebs,[...]. Lancet Oncol 2020
63
3

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Ciara C O'Sullivan, Dominic H Moon, Elise C Kohn, Jung-Min Lee. Front Oncol 2014
71
3

Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Stella Capriglione, Daniela Luvero, Francesco Plotti, Corrado Terranova, Roberto Montera, Giuseppe Scaletta, Teresa Schirò, Gianmarco Rossini, Pierluigi Benedetti Panici, Roberto Angioli. Med Oncol 2017
29
3

Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Federica Tomao, Erlisa Bardhi, Anna Di Pinto, Carolina Maria Sassu, Elena Biagioli, Maria Cristina Petrella, Innocenza Palaia, Ludovico Muzii, Nicoletta Colombo, Pierluigi Benedetti Panici. Cancer Treat Rev 2019
32
3

Chemotherapy-free treatments: are we ready for prime time?
D Lorusso, S Pignata, A Gonzalez-Martin. Ann Oncol 2019
2
50


Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology.
N Wald, N Bordry, P G Foukas, D E Speiser, E Goormaghtigh. Biochim Biophys Acta 2016
14
7

Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy.
Lei Li, Xiaoning Bi, Hengzi Sun, Simiao Liu, Mei Yu, Ying Zhang, Shifu Weng, Limin Yang, Yanan Bao, Jinguang Wu,[...]. J Ovarian Res 2018
14
7

Infrared Microspectroscopy and Imaging Analysis of Inflammatory and Non-Inflammatory Breast Cancer Cells and Their GAG Secretome.
Hossam Taha Mohamed, Valérie Untereiner, Gianfelice Cinque, Sherif Abdelaziz Ibrahim, Martin Götte, Nguyet Que Nguyen, Romain Rivet, Ganesh D Sockalingum, Stéphane Brézillon. Molecules 2020
3
33

Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins.
Stéphane Brézillon, Katarzyna Pietraszek, François-Xavier Maquart, Yanusz Wegrowski. FEBS J 2013
64
3

Ovarian cancer ascites-derived vitronectin and fibronectin: combined purification, molecular features and effects on cell response.
Ludovic Carduner, Rémy Agniel, Sabrina Kellouche, Cédric R Picot, Cécile Blanc-Fournier, Johanne Leroy-Dudal, Franck Carreiras. Biochim Biophys Acta 2013
13
7

Lumican is overexpressed in lung adenocarcinoma pleural effusions.
Rocco Cappellesso, Renato Millioni, Giorgio Arrigoni, Francesca Simonato, Brasilina Caroccia, Elisabetta Iori, Vincenza Guzzardo, Laura Ventura, Paolo Tessari, Ambrogio Fassina. PLoS One 2015
21
4

Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity.
Albin Jeanne, Thomas Sarazin, Magalie Charlé, Catherine Moali, Caroline Fichel, Camille Boulagnon-Rombi, Maïté Callewaert, Marie-Christine Andry, Eric Diesis, Frédéric Delolme,[...]. Cancers (Basel) 2021
1
100

Lumican: a new inhibitor of matrix metalloproteinase-14 activity.
Katarzyna Pietraszek, Aurore Chatron-Colliet, Stéphane Brézillon, Corinne Perreau, Anna Jakubiak-Augustyn, Hubert Krotkiewski, François-Xavier Maquart, Yanusz Wegrowski. FEBS Lett 2014
39
3

Using Fourier transform IR spectroscopy to analyze biological materials.
Matthew J Baker, Júlio Trevisan, Paul Bassan, Rohit Bhargava, Holly J Butler, Konrad M Dorling, Peter R Fielden, Simon W Fogarty, Nigel J Fullwood, Kelly A Heys,[...]. Nat Protoc 2014
609
3

Early events in the pathogenesis of epithelial ovarian cancer.
Charles N Landen, Michael J Birrer, Anil K Sood. J Clin Oncol 2008
310
3

Lumican Inhibits SNAIL-Induced Melanoma Cell Migration Specifically by Blocking MMP-14 Activity.
Marta Stasiak, Joanna Boncela, Corinne Perreau, Konstantina Karamanou, Aurore Chatron-Colliet, Isabelle Proult, Patrycja Przygodzka, Shukti Chakravarti, François-Xavier Maquart, M Anna Kowalska,[...]. PLoS One 2016
36
3

Treatment algorithm in patients with ovarian cancer.
I Vergote, H Denys, J De Greve, C Gennigens, K Van De Vijver, J Kerger, P Vuylsteke, J F Baurain. Facts Views Vis Obgyn 2020
1
100

Label-Free Infrared Spectral Histology of Skin Tissue Part I: Impact of Lumican on Extracellular Matrix Integrity.
Lise Nannan, Valérie Untereiner, Isabelle Proult, Camille Boulagnon-Rombi, Charlie Colin-Pierre, Ganesh D Sockalingum, Stéphane Brézillon. Front Cell Dev Biol 2020
2
50

Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression.
Sylvie Brassart-Pasco, Stéphane Brézillon, Bertrand Brassart, Laurent Ramont, Jean-Baptiste Oudart, Jean Claude Monboisse. Front Oncol 2020
45
3

Molecular polymorphism of lumican during corneal development.
P K Cornuet, T C Blochberger, J R Hassell. Invest Ophthalmol Vis Sci 1994
101
3

Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response.
Dragana Nikitovic, Antonis Papoutsidakis, Nikos K Karamanos, George N Tzanakakis. Matrix Biol 2014
65
3



Lumican - derived peptides inhibit melanoma cell growth and migration.
Katarzyna Pietraszek, Stéphane Brézillon, Corinne Perreau, Maria Malicka-Błaszkiewicz, François-Xavier Maquart, Yanusz Wegrowski. PLoS One 2013
31
3

Label-Free Infrared Spectral Histology of Skin Tissue Part II: Impact of a Lumican-Derived Peptide on Melanoma Growth.
Stéphane Brézillon, Valérie Untereiner, Hossam Taha Mohamed, Estelle Ahallal, Isabelle Proult, Pierre Nizet, Camille Boulagnon-Rombi, Ganesh D Sockalingum. Front Cell Dev Biol 2020
4
25

Differential MMP-14 Targeting by Lumican-Derived Peptides Unraveled by In Silico Approach.
Jonathan Dauvé, Nicolas Belloy, Romain Rivet, Nicolas Etique, Pierre Nizet, Katarzyna Pietraszek-Gremplewicz, Konstantina Karamanou, Manuel Dauchez, Laurent Ramont, Stéphane Brézillon,[...]. Cancers (Basel) 2021
1
100

Characterization of inflammatory breast cancer: a vibrational microspectroscopy and imaging approach at the cellular and tissue level.
Hossam Taha Mohamed, Valérie Untereiner, Isabelle Proult, Sherif Abdelaziz Ibrahim, Martin Götte, Mohamed El-Shinawi, Mona Mostafa Mohamed, Ganesh D Sockalingum, Stéphane Brézillon. Analyst 2018
9
11


Lumican, a small leucine-rich proteoglycan.
Dragana Nikitovic, Paulos Katonis, Aristidis Tsatsakis, Nikos K Karamanos, George N Tzanakakis. IUBMB Life 2008
91
3

Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition.
Konstantina Karamanou, Marco Franchi, Zoi Piperigkou, Corinne Perreau, Francois-Xavier Maquart, Demitrios H Vynios, Stéphane Brézillon. Sci Rep 2017
37
3

Assessment of the denaturation of collagen protein concentrates using different techniques.
Victor Perez-Puyana, Francisco J Ostos, Pilar López-Cornejo, Alberto Romero, Antonio Guerrero. Biol Chem 2019
7
14

Combination of FTIR spectral imaging and chemometrics for tumour detection from paraffin-embedded biopsies.
Elodie Ly, Olivier Piot, Rolf Wolthuis, Anne Durlach, Philipe Bernard, Michel Manfait. Analyst 2008
71
3

Lumican Inhibits In Vivo Melanoma Metastasis by Altering Matrix-Effectors and Invadopodia Markers.
Konstantina Karamanou, Marco Franchi, Isabelle Proult, Romain Rivet, Demitrios Vynios, Stéphane Brézillon. Cells 2021
6
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.